This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Aetiology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Obstructive sleep apnoea occurs in three groups of children:

  • those with adenotonsillar hypertrophy
    • main issue correlated with OSA in children (1)
    • often there is no underlying medical diagnosis
    • peak incidence is seen in children aged 3 to 6 years (which coincides with the time when the adenoids and tonsils undergo hypertrophy)
  • those who are obese
    • pathogenesis is multifactorial
    • exact mechanism is unclear but pharyngeal adipose tissue and decreased respiratory capacity are thought to contribute
  • those who have congenital abnormalities
    • Down's syndrome
      • OSA may be caused by an abnormally narrow upper airway and reduced pharyngeal muscle tone.
      • regular screening for obstructive sleep apnoea is recommended since around two thirds of children will have have some form of sleep disordered breathing
    • neuromuscular disease
    • craniofacial abnormalities
    • achondroplasia
    • mucopolysaccharidoses
    • Prader-Willi syndrome (2,3)

Reference:

(1) Giuca MR, et al. Pediatric Obstructive Sleep Apnea Syndrome: Emerging Evidence and Treatment Approach. ScientificWorldJournal. 2021 Apr 23;2021:5591251.

(2) Powell S et al. Paediatric obstructive sleep apnoea. BMJ. 2010;340:c1918

(3) Powell S. Clinical review: Paediatric obstructive sleep apnoea. GPonline 2011

Create an account to add page annotations

Create a free account

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.